pyrroles has been researched along with Malignant Fibrohistiocytic Tumors in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kamposioras, K; Mauri, D; Panou, C; Tsali, L; Valachis, A | 1 |
| Agresta, S; Antonia, S; Calitri, CE; Chiappori, A; D'Amato, G; Dean, M; Garrett, C; Han, G; Mahmood, ST; Schell, MJ; Vigil, CE; Zhao, X | 1 |
1 trial(s) available for pyrroles and Malignant Fibrohistiocytic Tumors
| Article | Year |
|---|---|
Phase II study of sunitinib malate, a multitargeted tyrosine kinase inhibitor in patients with relapsed or refractory soft tissue sarcomas. Focus on three prevalent histologies: leiomyosarcoma, liposarcoma and malignant fibrous histiocytoma.
Topics: Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Histiocytoma, Malignant Fibrous; Humans; Indoles; Leiomyosarcoma; Liposarcoma; Male; Neoplasm Metastasis; Protein Kinase Inhibitors; Pyrroles; Recurrence; Retreatment; Sarcoma; Sunitinib; Survival Rate | 2011 |
1 other study(ies) available for pyrroles and Malignant Fibrohistiocytic Tumors
| Article | Year |
|---|---|
Tyrosine kinase inhibitors in treatment of fibrous histiocytoma.
Topics: Antineoplastic Agents; Bone Neoplasms; Histiocytoma, Malignant Fibrous; Humans; Indoles; Kidney Neoplasms; Lung; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrroles; Sunitinib | 2009 |